ACIP VOTES TO EXPAND RECOMMENDATION FOR PFIZER’S RSV VACCINE ABRYSVO® TO INCLUDE ADULTS AGED 50 TO 59 AT INCREASED RISK OF DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.